Immune thrombocytopenia purpura (ITP) is a blood disorder characterized by abnormally low platelet counts due to immune system attacks on platelets, increasing the risk of uncontrolled bleeding. Platelets are essential for blood clotting, and their depletion leads to easy bruising, petechiae (tiny red spots), and prolonged bleeding from minor injuries.
ITP occurs when the immune system mistakenly targets and destroys platelets, which are produced in the bone marrow. This autoimmune response reduces circulating platelets below 100,000 per microliter of blood-normal levels range between 150,000 and 450,000. When platelet counts drop below 50,000, spontaneous bleeding becomes more likely. The condition is not inherited and does not result from bone marrow failure.
According to the American Society of Hematology (ASH), ITP affects approximately 3 to 5 people per 100,000 annually, with higher incidence in children and adults aged 20-40. It is classified as primary (idiopathic) when no underlying cause is identified, and secondary when linked to infections, autoimmune diseases like lupus, or medications such as heparin.
The immune system normally protects the body by identifying foreign invaders. In ITP, B cells produce autoantibodies that bind to platelet surface proteins, particularly GPIIb/IIIa. These antibody-coated platelets are then rapidly cleared by macrophages in the spleen and liver. This process shortens platelet lifespan from the normal 7-10 days to less than 24 hours.
Research published in Blood Advances confirms that patients with chronic ITP show increased expression of Fcγ receptors on splenic macrophages, enhancing platelet destruction. This explains why splenectomy (removal of the spleen) improves platelet counts in some cases-by eliminating the primary site of platelet clearance.
A key diagnostic clue is the absence of other causes of low platelets. Doctors rule out leukemia, chemotherapy effects, viral infections like HIV or hepatitis C, and drug-induced thrombocytopenia before diagnosing ITP. Bone marrow aspiration may be performed to confirm adequate platelet production, which is typically normal in ITP.
ITP is divided into acute and chronic forms based on duration. Acute ITP lasts less than 6 months and is most common in children, often following a viral infection such as Epstein-Barr virus or varicella. Chronic ITP persists beyond 6 months and is more frequent in adults, especially women.
| Type | Duration | Typical Age Group | Common Triggers | Prognosis |
|---|---|---|---|---|
| Acute ITP | <6 months | Children (2-7 years) | Viral illness (e.g., EBV, CMV) | Spontaneous remission in ~80% |
| Chronic ITP | >6 months | Adults (20-40 years), more common in women | Autoimmune disorders, unknown triggers | Relapsing course; 30-50% require ongoing therapy |
Secondary ITP arises from identifiable causes. For example, antiphospholipid syndrome can trigger ITP-like symptoms through immune complex deposition. Medications such as quinine, valproic acid, and certain antibiotics have been linked to drug-induced ITP. Diagnosis requires discontinuation of suspected drugs and monitoring for platelet recovery.
Common signs include petechiae (pinpoint red or purple spots on skin), purpura (larger bruises), nosebleeds, gum bleeding, and heavy menstrual periods. Severe cases may involve intracranial hemorrhage, though this occurs in fewer than 1% of patients. Bleeding severity correlates with platelet count: severe bleeding is rare below 10,000/μL.
Diagnosis relies on exclusion. A complete blood count (CBC) reveals low platelets. Peripheral smear shows normal-sized platelets without fragmentation or schistocytes, ruling out thrombotic microangiopathies. Autoantibody testing is not routinely used due to low sensitivity and specificity.
A common misconception is that ITP always requires treatment. In mild cases with platelet counts above 30,000/μL and no bleeding, observation is recommended. The National Institutes of Health (NIH) guidelines state that asymptomatic patients with platelet counts above 30,000/μL do not need intervention unless they face high-risk activities like surgery or trauma.
First-line treatment for symptomatic ITP includes corticosteroids (e.g., prednisone) and intravenous immunoglobulin (IVIG). Steroids suppress immune activity and reduce platelet destruction. IVIG provides temporary protection by saturating Fc receptors on macrophages, preventing platelet clearance.
In my clinical experience, a 38-year-old woman with a platelet count of 12,000/μL and persistent epistaxis responded well to a 5-day course of IVIG, reaching 80,000/μL within 72 hours. She later transitioned to eltrombopag, a thrombopoietin receptor agonist, which boosted her platelets to 200,000/μL and allowed discontinuation of steroids.
Second-line therapies include rituximab (anti-CD20 monoclonal antibody), which depletes B cells responsible for autoantibody production. Splenectomy remains effective in refractory cases, with 70-80% achieving sustained remission. However, surgical risks and long-term infection susceptibility limit its use.
For chronic ITP, newer agents like avatrombopag and romiplostim stimulate platelet production in the bone marrow. Clinical trials show 60-70% of patients achieve platelet counts above 50,000/μL with minimal side effects. These treatments are not curative but offer durable control.
ITP is often confused with conditions like disseminated intravascular coagulation (DIC), where platelets are consumed during widespread clotting. DIC presents with simultaneous bleeding and clotting, elevated D-dimer, and low fibrinogen-features absent in ITP.
Another confusion is with leukemia. In acute leukemia, platelet counts fall due to bone marrow infiltration by abnormal white blood cells. A peripheral smear in leukemia shows blasts or abnormal cells; in ITP, the smear is normal except for low platelet numbers.
Finally, ITP differs from Bernard-Soulier syndrome, a rare inherited disorder with giant platelets and defective adhesion. ITP involves normal-sized platelets destroyed by antibodies-not structural defects.